Cedars-Sinai Technology Ventures has had 114 patents issued for the fiscal year 2021 and has 511 active technologies under development, as of July 2021
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
It will be the first and only global office for traditional medicine in the world
Price was the key driver for the period
Under this year’s theme of ‘Kidney Health For All’, ISN along with AstraZeneca aims to generate large scale awareness and educate people about ways to improve kidney health
This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
Subscribe To Our Newsletter & Stay Updated
